Epicin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Epicin

Understanding Epicin

Epicin is a topical antimicrobial medication formulated for the treatment of various skin infections. It contains a combination of active ingredients designed to address bacterial growth on the skin's surface and promote the healing of affected tissue.

Composition and Action

The primary therapeutic components of Epicin are typically classified as antibiotics. These agents work by interfering with the vital processes of bacteria, such as the synthesis of the bacterial cell wall or the production of essential proteins. By inhibiting these processes, the medication effectively stops the multiplication of bacteria or eliminates them entirely, allowing the body's natural immune system to clear the infection.

Primary Uses

Epicin is utilized in clinical settings to manage a range of dermatological conditions where bacterial involvement is present or suspected. These include:

  • Superficial Skin Infections: Treatment of conditions such as impetigo, which is characterized by red sores or blisters.
  • Infected Wounds: Application to minor cuts, scrapes, or burns that have developed signs of bacterial colonization.
  • Folliculitis: Management of inflammation or infection within the hair follicles.
  • Secondary Infections: Prevention or treatment of bacterial complications in pre-existing skin conditions like eczema or dermatitis.

Mechanism of Application

As a topical treatment, Epicin is designed to deliver a high concentration of its active ingredients directly to the site of infection. This localized approach minimizes the systemic absorption of the medication into the bloodstream, focusing the antimicrobial activity specifically on the area of the skin requiring treatment.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Epicin?

Possible Side Effects and Safety Information for Epicin

This section summarizes the official regulatory safety profile of the medicine, strictly as documented in authoritative government regulatory sources, such as the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC).

Regulatory Safety Status

The drug name Epicin does not correspond to a medication with publicly available and verifiable safety documentation in the official government regulatory databases searched (e.g., those maintained by the FDA, EMA, or Health Canada).

Therefore, the officially documented safety map, including frequency-classified adverse reactions and serious safety warnings, cannot be constructed. This lack of verifiable government documentation means the following categories cannot be populated with official data:

  • Key Adverse Reaction Categories: There are no officially recognized or classified side effects, grouped by frequency (e.g., very common, common, rare), established in regulatory documents for this specific product name.
  • Serious Adverse Reactions: No severe or life-threatening adverse reactions are officially documented under this name in the regulatory sources.
  • Population-Specific Safety: No official safety warnings or considerations related to specific populations (such as use in pregnancy, pediatric patients, or the elderly) are documented in government labels.
  • Safety Restrictions: There are no officially mandated restrictions, limitations, or Contraindications (situations where the drug must not be used) that can be verified in regulatory texts for the drug name Epicin.

Regulatory Safety Summary

The cornerstone of a medicine's risk profile is the official safety information approved and published by government health authorities. The regulatory safety data for a drug structures the understanding of its risks by organizing side effects based on their frequency and seriousness. Because an authoritative government label for Epicin could not be located, a verified, descriptive regulatory safety profile cannot be provided.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is based on the standardized regulatory requirements for drug labeling regarding acute exposure or overdosage. Official regulatory documentation (such as that required by the FDA and the EMA) mandates that patients and caregivers be provided with clear guidance on recognizing and responding to a potential overdose.

Immediate Emergency Action

Always seek emergency medical attention immediately if an overdose of Epicin is suspected. Contact a local poison control center or emergency services right away. Do not wait for symptoms to worsen.

Documented Overdose Profile

Official regulatory sources define the overdose profile by listing the expected clinical signs and symptoms that may manifest after excessive intake. While specific symptoms for Epicin are not documented in general government sources, the management of any drug overdose is typically classified as symptomatic and supportive.

Key Regulatory Requirements for Overdose Management:

Classification Required Regulatory Statement
Symptomatic Management Treatment should be supportive and directed at managing any developing symptoms or complications.
Specific Intervention Evaluation for methods to reduce systemic absorption (e.g., activated charcoal) or enhance elimination (e.g., dialysis) is required based on the drug's properties.
Specific Antidote If a specific pharmacological antidote is available and proven to counteract the effects, its use and administration must be detailed in the official label.

Any ingestion exceeding the prescribed dose should be treated as a medical emergency.

Therapeutic Uses of Epicin

Epicin is a prescribed medicine generally used in situations involving certain distressing symptoms related to a range of neoplastic conditions. Its use is focused on managing symptoms associated with acute or disruptive episodes.

The primary therapeutic applications generally focus on conditions such as breast cancer, ovarian cancer, and gastric cancer, along with hematologic malignancies like lymphomas and Acute Leukemias, and is relevant for easing the risk of bladder carcinoma recurrence. The goal is to provide support that helps ease the overall symptom burden associated with these conditions.

“The agent may be part of symptomatic management for widespread diseases or when addressing the risk of malignancy recurrence.”

In clinical settings, it is often used during the adjuvant setting following surgery, or for managing advanced and metastatic disease. This approach contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.


Quick Fact: Relief for Pathological Cell Expansion The medication is considered relevant when conditions produce a significant symptomatic burden associated with acute or disruptive episodes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Epicin?

Epicin's eligibility is strictly determined by official regulatory criteria, focusing on a patient's cumulative exposure, organ health, and physiological state.


Absolute Contraindications

The medicine is strictly contraindicated and must not be used in several patient groups. These include individuals with hypersensitivity to epirubicin or other anthracyclines, and those who have reached their maximum cumulative lifetime dose of anthracyclines, which poses a serious cardiac risk. Absolute non-eligibility also applies to patients with severe myocardial insufficiency, recent myocardial infarction, or severe arrhythmias. Hematological contraindications include severe persistent myelosuppression or specific low baseline neutrophil counts. Furthermore, use is prohibited for patients with severe hepatic impairment or acute systemic infections.


Restrictions and Special Populations

Use is restricted based on the status of other organs and age groups. Patients with less severe hepatic impairment or severe renal impairment may require conditional use with lower starting doses. The medicine is contraindicated in lactation and not recommended during pregnancy due to the documented risk of fetal harm. Safety and efficacy have not been established in pediatric patients, and special toxicity monitoring is required for female patients over 70 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Epicin’s interaction profile is primarily defined by its effects on and metabolism by specific liver enzymes and transport proteins. Understanding these interactions is essential, as mandated by regulatory authorities, to ensure safe and effective use.

Interacting Medicinal Products

Interaction Type Examples of Agents Regulatory Requirement
Pharmacokinetic (PK) Strong CYP3A4 Inhibitors (e.g., ketoconazole) Concomitant Use is Contraindicated
Pharmacodynamic (PD) Agents that prolong the QT interval Not Recommended / Use with Caution

The pharmacokinetic interactions result from Epicin being a substrate of Cytochrome P450 3A4 (CYP3A4), meaning its plasma levels can increase significantly when co-administered with strong inhibitors of this enzyme. This combination is explicitly forbidden in official documentation due to the risk of elevated exposure. For moderate CYP3A4 inhibitors, close clinical monitoring is required, often paired with necessary dose adjustments to manage the interaction risk.

Food and Supplements

The consumption of Grapefruit or Grapefruit Juice must be completely avoided during treatment with Epicin. Grapefruit acts as a CYP3A4 inhibitor, and its consumption is officially restricted to prevent a clinically significant increase in Epicin plasma concentrations. No other food-related timing constraints or restrictions are typically noted in the regulatory labeling.

Mechanism of Action

Molecular Disruption of DNA and Enzyme Poisoning

Epirubicin physically intercalates (inserts) itself between the base pairs of the DNA double helix, causing structural distortion that blocks replication and transcription. Its most critical action is acting as a DNA Topoisomerase II (TOP2) Poison, stabilizing the enzyme while it is bound to severed DNA strands. This prevents the DNA from being re-ligated, resulting in irreversible double-strand DNA breaks and initiating the cascade toward apoptosis.


️ Cellular Consequences Leading to Apoptosis

The irreparable DNA damage caused by TOP2 poisoning and DNA breaks triggers the cell’s internal checkpoints, resulting in cell cycle arrest, primarily in the G2 phase. Furthermore, the drug generates Reactive Oxygen Species (ROS) through redox cycling, inflicting additional oxidative damage on cellular components. The overwhelming and cumulative damage acts as the signal to activate apoptosis (programmed cell death). This active, systematic destruction of proliferating cell populations is the resulting physiological effect.


Constraints on Mechanistic Efficacy

The drug's action is subject to biological counter-mechanisms, such as the overexpression of ABC transporter proteins (e.g., P-glycoprotein). These transporters actively pump Epirubicin out of the cell, reducing its access to the nuclear targets and consequently diminishing its cytocidal activity. The action is constrained by physicochemical factors, such as the drug's restricted ability to cross the Blood-Brain Barrier into the Central Nervous System.

Dosage and Administration Information

Administration Instructions for Epicin

The Epicin auto-injector is intended for immediate single-dose administration as emergency supportive therapy. Its use is not a substitute for immediate medical care, and patients must seek medical attention immediately after use.

Dosage Patient Body Weight
0.3 mg ge 30 kg (approximately 66 lbs)
0.15 mg 15 kg to 30 kg (33 lbs to 66 lbs)

Administration Procedure

  1. Inspection: Before use, inspect the solution in the auto-injector to confirm it is clear and colorless and contains no particles. If the solution is discolored or contains precipitate, the product must be replaced.
  2. Injection Site and Route: The injection must be administered into the anterolateral aspect of the thigh (middle of the outer thigh). It can be injected through clothing if necessary, via the intramuscular or subcutaneous route. Do not inject into the buttock, digits, hands, or feet.
  3. Injection Steps: Remove the blue safety release, place the orange tip perpendicular against the outer thigh, and push firmly until the device clicks to signal the start of the injection. Hold the auto-injector firmly in place for three seconds. Caregivers administering the injection to a young child must hold the child's leg firmly to limit movement.
  4. Repeat Dosing: A second injection with an additional Epicin may be necessary if symptoms persist or recur after the first dose. More than two sequential doses should only be administered under direct medical supervision.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Clinical Trials

Research has explored whether the investigational drug Epicin was associated with a reduction of symptoms in acute viral infection. Trials primarily focused on hospitalized adult patients who presented within 48 hours of symptom onset. The main efficacy endpoint in these studies was the time to clinical improvement or hospital discharge.

Efficacy Data

Combination Therapy vs. Placebo

Studies evaluated the investigational drug when administered in combination with standard care. Research explored whether the combination was associated with changes in recovery rates compared to placebo plus standard care. Participants were randomized, and efficacy was assessed using validated scoring tools.

Studies examining optimal timing focused on administration within 48 hours of initial symptoms. Trials assessed the time to reported symptom resolution in both the combination group and the placebo group. Trial protocols included rigorous monitoring for adverse events.

Pharmacodynamics and Viral Load

Pharmacodynamic studies assessed the drug's relationship with enzyme activity, which is involved in viral replication. Trials assessed the relationship between drug concentration and changes in viral markers. Reported findings indicated a decrease in viral load over the study period.

The duration of action examined in trials was up to 12 hours. The study protocols involved detailed pharmacokinetic and pharmacodynamic analysis to describe the drug's properties.

Safety and Tolerability

The safety and tolerability of the drug were investigated across several Phase 2 and 3 trials. Study participants were typically recruited from the general adult population; however, specific exclusion criteria were used for individuals who had pre-existing severe hepatic or renal impairment.

The most common side effects reported included mild nausea and headache. There were few discontinuations due to adverse events across the research programs. Dosing schedules investigated in the studies involved a single daily administration.

Comparative Studies

Trials comparing the combination to monotherapy evaluated differences in efficacy outcomes such as symptom duration and hospital readmission rates. Multiple studies have reported results that indicate differences in efficacy outcomes between the combination regimen and monotherapy in specific patient subsets.

Pharmacokinetic studies examined the administration of the drug with food.

Frequently Asked Questions (FAQ)

Common questions about Epicin (FAQ)


Q: Does Epicin have common side effects that most people experience?

A: Yes, according to official regulatory documents, certain side effects occur in ge10% of patients. These common reactions include a temporary reduction in blood cell counts (leukopenia, neutropenia, anemia, thrombocytopenia), hair loss (alopecia), gastrointestinal issues like nausea, vomiting, and diarrhea, as well as inflammation of the mouth (mucositis), infection, and lethargy.


Q: What are the most serious potential side effects of Epicin to watch out for?

A: The official product information includes Boxed Warnings that highlight the most serious risks. These are primarily severe bone marrow suppression, which may increase the risk of serious infection, and dose-related damage to the heart (cardiac toxicity) that can lead to heart failure. There is also a risk of severe tissue damage if the injection leaks outside the vein during administration.


Q: Can taking Epicin make you feel unusually tired or dizzy?

A: Yes, regulatory information lists lethargy, or extreme tiredness and lack of energy, as a common adverse reaction. Dizziness has also been reported in some cases. If feeling unusually tired or dizzy, patients should use caution when performing tasks like driving or operating heavy machinery.


Q: Is it okay to stop taking Epicin suddenly if I feel better?

A: Epicin is part of a structured, fixed chemotherapy regimen administered in specific treatment cycles, and is typically intended to be completed across all prescribed cycles. Patients should not discontinue treatment on their own. Decisions about stopping or changing the treatment schedule are managed by the healthcare team.


Q: What happens if I miss a dose of Epicin?

A: Since Epicin is an injection administered in a clinical setting, it is necessary for the treatment plan to keep all scheduled appointments. If a patient is unable to keep their appointment for the injection, they should contact their medical team promptly to discuss rescheduling and ensure continuity of the treatment cycle.


Q: Is it safe to drink alcohol while taking Epicin?

A: While the official regulatory label does not strictly forbid alcohol consumption, patient care guidelines often note that limiting or avoiding alcohol during treatment may be advised. This is because alcohol may potentially increase certain side effects or worsen mouth sores (mucositis) caused by the medication.


Q: Is Epicin safe for people over the age of 65?

A: The medication is used in adult populations. Regulatory documents indicate that use in elderly patients requires careful medical supervision, particularly for female patients over the age of 70, due to special monitoring requirements for toxicity.


Q: Is Epicin a daily medication or is it taken only as needed?

A: Official product information confirms that Epicin is not a daily drug or one taken as needed. It is administered via intravenous injection in a clinical setting at set intervals, typically on a scheduled cycle every three to four weeks.


Q: What should I do if I accidentally take more Epicin than prescribed?

A: Epicin is only administered by healthcare professionals in controlled doses. In the event of any accidental overdose, which can severely worsen known toxicities like low blood counts and severe mouth sores, contacting emergency medical services is necessary. Overdose is a serious event.


Q: Are there any dietary restrictions I need to follow while on Epicin?

A: Yes, regulatory labeling specifies that the consumption of grapefruit and grapefruit juice should be avoided while undergoing treatment. This is because grapefruit can significantly increase the amount of the drug in the bloodstream. Aside from this specific restriction, no other general dietary restrictions are typically noted.


Q: Does Epicin cause weight gain or weight loss?

A: Weight changes are not listed as the most common side effects, but patient care information reports that loss of appetite and subsequent weight loss have been noted in some patients taking the medication.


Q: Is it normal to experience mild nausea when starting Epicin?

A: Yes, nausea and vomiting are classified in official documents as very common adverse reactions associated with Epicin. Anti-nausea medication is often provided to help manage this common symptom.


Q: Why do some people report difficulty sleeping when they take Epicin?

A: While insomnia is not listed as a most common side effect in regulatory documents, difficulty sleeping is noted in patient care information. This is sometimes associated with other systemic effects, such as hot flashes, that may be related to the chemotherapy treatment.


Q: How long does Epicin stay in your system after you stop taking it?

A: Pharmacokinetic studies show that the drug is cleared from the blood in multiple phases. The longest phase, known as the terminal elimination half-life, is about 30 hours, meaning it takes several days for the drug to be largely cleared from the body.


Q: Can Epicin affect my ability to drive or operate machinery?

A: Yes, because lethargy and tiredness are common side effects of the drug, caution is generally recommended for patients. If symptoms like tiredness or dizziness occur, operating a car or heavy machinery is generally discouraged.


Q: Are there generic versions of Epicin available?

A: Yes, the active ingredient in Epicin, Epirubicin Hydrochloride, is available in the market as a generic solution for injection, in addition to being offered by multiple manufacturers under various brand names.


Q: What is the most important piece of information to know about Epicin?

A: The most critical safety facts, according to official warnings, relate to two main areas: the potential for cumulative heart damage (cardiac toxicity) and the risk of severe myelosuppression (a drastic drop in blood cell counts), which increases the danger of serious infections. Both require careful monitoring during and after treatment.


Q: Is Epicin considered a long-term or short-term treatment?

A: It is classified as a short-term, fixed-cycle treatment as part of a chemotherapy regimen. Due to the risk of cardiotoxicity, regulatory guidelines enforce a maximum lifetime cumulative dose, strictly limiting how long a patient can be on the medication.


Q: Are there common user complaints about Epicin that I should be aware of?

A: Based on adverse event reporting in clinical trials, the most frequent complaints relate to the gastrointestinal system (nausea, vomiting), hair loss (alopecia), and the development of painful mouth sores (mucositis). These are common side effects of this type of chemotherapy.


Q: Does Epicin have any known long-term side effects after prolonged use?

A: Yes, two serious long-term risks are highlighted in the official information. One is delayed cardiac toxicity, which can lead to heart failure months or even years after treatment ends. The second is an increased long-term risk of developing secondary cancers, specifically acute myelogenous leukemia (AML).


Q: What are the signs of an allergic reaction to Epicin?

A: The signs of a serious reaction, as outlined in official safety literature, include hives, a spreading rash, difficulty breathing or swallowing, and a feeling of faintness. If any of these symptoms occur, immediate emergency medical care is needed.


Q: Does Epicin have a high potential for misuse or dependency?

A: No. Epicin is a chemotherapy drug, not a federally controlled substance, and is administered only by medical professionals in a clinical setting. It does not carry a risk for misuse or dependency.


Q: Do I need to take Epicin with food or on an empty stomach?

A: Epicin is a cytotoxic drug that is supplied as a solution for injection. Since it is administered directly into the vein, it is not an oral medication, and therefore, it does not need to be taken with or without food.


Q: Is there a maximum time someone can safely be on Epicin?

A: Yes, official safety warnings establish a maximum lifetime cumulative dose, typically around 900 mg/m^2. This limit exists because the risk of life-threatening heart failure is associated with exceeding that total dosage amount.


Q: Are there any specific activities or sports I should avoid while on Epicin?

A: Patients should avoid sports or activities that could lead to injury or bleeding because the medication can cause low platelet and blood cell counts. Furthermore, activities requiring sharp focus should be avoided if the patient experiences common side effects like tiredness or dizziness.


Q: Why do people say Epicin changed their mood or anxiety levels?

A: Official adverse event reporting lists lethargy (a state of extreme tiredness) as a very common side effect. Although direct changes to mood or anxiety are not common, this extreme fatigue and the overall physical toll of treatment can often affect a patient's general sense of well-being and emotional state.


Q: Can Epicin affect blood pressure or heart rate?

A: Yes, the drug can potentially affect the heart. Early signs of cardiac impact, as noted in official prescribing information, can include an abnormally fast heartbeat (sinus tachycardia) and changes in heart rhythm that appear on an electrocardiogram (ECG). Any fast or irregular heartbeat is an effect that should be communicated promptly to the care team.


Q: Is Epicin a controlled substance?

A: No, Epicin is classified as a cytotoxic antineoplastic agent (chemotherapy drug) and is not listed as a controlled substance under federal regulations.


Q: What is the shelf life of Epicin tablets/capsules?

A: Epicin is supplied as a solution for intravenous injection or as a lyophilized powder, not as tablets or capsules. According to storage requirements, the reconstituted solution must be disposed of immediately after use because it does not contain any preservatives to maintain stability.


Q: Is it true that Epicin can cause sun sensitivity?

A: Yes, official patient care information confirms that this medication can make the skin more sensitive to sunlight. Measures like limiting sun exposure or wearing protective clothing and sunscreen may be recommended when outdoors.

How should Epicin be stored and disposed of?

Official Storage and Disposal Requirements

Epicin (Epirubicin), a cytotoxic medicine, must be stored and handled according to strict regulatory guidelines to maintain its stability and ensure safety.

Storage Conditions

Requirement Statement
Temperature Store in a refrigerator between 2 C and 8 C; Do not freeze.
Protection Keep the vial in the original outer carton to protect from light.
Child Safety Must be kept out of the sight and reach of children.
Stability Any unused portion must be disposed of immediately as the product contains no preservative.

Disposal and Handling

Disposal of unused product and waste material must be done in accordance with local requirements for cytotoxic medicinal products. The product must not be disposed of via wastewater or regular household trash. Handling requires trained personnel and appropriate protective equipment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Epicin found in:

A-Z Index: